Research and development

Sirnaomics Promotes Francois Lebel, M.D. to Chief Medical Officer

Retrieved on: 
Friday, December 1, 2023
MedImmune, Skin, Research and development, Organization, Food, Public key certificate, RNA interference, Physician, Royal college, Squamous-cell carcinoma, Molecular biology, McGill University, Internal medicine, Therapy, University, Harvard Medical School, Development, Drug development, Pharmaceutical industry, Chiron

and Suzhou, China, Dec. 1, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company"; stock code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today announced the promotion of Dr. Francois Lebel, M.D., to Chief Medical Officer.

Key Points: 
  • and Suzhou, China, Dec. 1, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company"; stock code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today announced the promotion of Dr. Francois Lebel, M.D., to Chief Medical Officer.
  • Dr. Lebel enters this new role after serving as Senior Vice President for preclinical and clinical development since July 2023.
  • "I am honored to lead Sirnaomics' RNAi pipeline through clinical development, building upon my experiences with the Company, and with outside investigators and international regulatory bodies, I hope my experiences of successfully achieving eight product marketing approvals will bring Sirnaomics to the commercial stage," said Dr. Lebel, M.D., Chief Medical Officer of Sirnaomics.
  • His most recent senior leadership roles include Executive Vice President for Research & Development and Chief Medical Officer Spectrum, where he was responsible for Preclinical and Clinical Development, Regulatory Affairs and Pharmacovigilance/Drug Safety.

Zoomd Technologies Reports Third Quarter 2023 Financial Results, Driven by Strong Adjusted EBITDA Growth

Retrieved on: 
Thursday, November 30, 2023
EBITDA, Interest, Acquisition, Conference call, Bank statement, Acceleration, Cryptocurrency, Administration, Research and development, Martech, Probability, Research, IGaming Business, Advertising, SEDAR, Development, Operating cost, OTC, Transport, Bookkeeping, Video game, USD, Conference

VANCOUVER, British Columbia, Nov. 30, 2023 /PRNewswire/ -- Zoomd Technologies Ltd. (TSXV: ZOMD) (OTC: ZMDTF) and its wholly owned subsidiary Zoomd Ltd. (collectively, "Zoomd" or the "Company"), the marketing technology (MarTech) user-acquisition and engagement platform, today reported its financial results for the three and nine month periods ended September 30, 2023. The Company's financial statements and management discussion and analysis ("MD&A") are available on SEDAR under the Company's profile. All currency references in this press release are in USD.

Key Points: 
  • VANCOUVER, British Columbia, Nov. 30, 2023 /PRNewswire/ -- Zoomd Technologies Ltd. (TSXV: ZOMD) (OTC: ZMDTF) and its wholly owned subsidiary Zoomd Ltd. (collectively, "Zoomd" or the "Company"), the marketing technology (MarTech) user-acquisition and engagement platform, today reported its financial results for the three and nine month periods ended September 30, 2023.
  • Adjusted EBITDA for the three months ended September 30, 2023, was $575,000 as compared with Adjusted EBITDA of $15,000 for the three months ended September 30, 2022, reflecting cost savings initiatives.
  • As of September 30, 2023, the Company's cash and cash equivalents amounted to $1.5 million, and no long-term debt.
  • Amit Bohensky, Founder and Chairman, will hold a conference call to discuss the quarter's financial results at 11AM ET on November 30, 2023.

Fluidx Medical Reveals New Embolic Platform for Internal Bleeding, Tumor Treatment, and Other Uses

Retrieved on: 
Thursday, November 30, 2023
GPX, Aneurysm, Embolism, Research and development, Risk, Fistula, Tissue, Patient, Refrigeration, Medicine, Internal bleeding, Interventional radiology, ULTRA, Neoplasm, Blood, IDE, Birth, Heel, Investigational device exemption, Investigator's brochure, Uterine fibroid, Medical device, Medical imaging

SALT LAKE CITY, Nov. 30, 2023 /PRNewswire/ -- Fluidx Medical today released information about their new ULTRA™ embolic platform designed to make therapeutic embolization procedures safer, better, and faster. 

Key Points: 
  • SALT LAKE CITY, Nov. 30, 2023 /PRNewswire/ -- Fluidx Medical today released information about their new ULTRA™ embolic platform designed to make therapeutic embolization procedures safer, better, and faster.
  • "Embolic particles are hard to visualize during delivery, increasing the risk of off-target embolization and leading to unintended harm of nearby tissues."
  • "ULTRA is visible under x-ray giving clinicians greater control and visualization of the embolic to ensure safe, accurate delivery."
  • The success of the ULTRA embolic platform follows on the heels of another large milestone for Fluidx Medical, as their flagship product the GPX Embolic Device is currently under Investigational Device Exemption (IDE) review with the FDA.

Wishpond Reports Continued Revenue and Adjusted EBITDA Growth in Q3-2023

Retrieved on: 
Thursday, November 16, 2023
Acquisition, Propel, Interim, Earnout, Bank statement, Acceleration, Research and development, Financial statement, Consultant, Marketing, Advertising, Social media, Adjustment, SEDAR, MD, Partnership, Software as a service, Growth, AI, MD Helicopters MD Explorer, MRR, SMB, Fiverr, Optimism, Bookkeeping, Beauty salon, Video game, Bank, Sales, Research

Wishpond achieved Adjusted EBITDA of $0.3 million, representing the fifth quarter in a row of positive Adjusted EBITDA.

Key Points: 
  • Wishpond achieved Adjusted EBITDA of $0.3 million, representing the fifth quarter in a row of positive Adjusted EBITDA.
  • Wishpond achieved revenue of $5.8 million in Q3-2023 and expects continued growth and improved cash flows in the last quarter of 2023.
  • Ali Tajskandar further adds, "In the third quarter we continued our streak of achieving positive Adjusted EBITDA for the fifth quarter in a row.
  • Wishpond's cost optimization efforts over the past year have contributed to the Company's continued positive Adjusted EBITDA profile.

PepsiCo Sets Goals to Further Reduce Sodium and Deliver More Diverse Ingredients in Convenient Foods Portfolio

Retrieved on: 
Tuesday, November 14, 2023
World Health Organization, PepsiCo, Research and development, Food, Spice, Seed, WHO, Vegetable, Research, Lammers, PEP, Grain boundary strengthening, Nut, Farmer, Food industry, Development, Disability, Taste, Sodium, Renewable energy, Salt

PepsiCo aims for at least 75% of its global convenient foods portfolio volume to meet or be below category sodium targets by 2030.

Key Points: 
  • PepsiCo aims for at least 75% of its global convenient foods portfolio volume to meet or be below category sodium targets by 2030.
  • Excess sodium intake is a leading risk factor for diet-associated disease and disability, prompting global public health authorities to call on the food industry to reduce sodium in their products.
  • The company aims to deliver 145 billion portions of diverse ingredients annually in its global convenient foods portfolio by 2030.
  • Maintaining Taste: Seasoning experts identify ingredients and study salt crystal shapes and sizes to optimize flavor while using less sodium.

PepsiCo Sets Goals to Further Reduce Sodium and Deliver More Diverse Ingredients in Convenient Foods Portfolio

Retrieved on: 
Tuesday, November 14, 2023
World Health Organization, PepsiCo, Research and development, Food, Spice, Seed, WHO, Vegetable, Research, Lammers, PEP, Grain boundary strengthening, Nut, Farmer, Food industry, Development, Disability, Taste, Sodium, Renewable energy, Salt

PepsiCo aims for at least 75% of its global convenient foods portfolio volume to meet or be below category sodium targets by 2030.

Key Points: 
  • PepsiCo aims for at least 75% of its global convenient foods portfolio volume to meet or be below category sodium targets by 2030.
  • Excess sodium intake is a leading risk factor for diet-associated disease and disability, prompting global public health authorities to call on the food industry to reduce sodium in their products.
  • The company aims to deliver 145 billion portions of diverse ingredients annually in its global convenient foods portfolio by 2030.
  • Maintaining Taste: Seasoning experts identify ingredients and study salt crystal shapes and sizes to optimize flavor while using less sodium.

OneConnect Announces Third Quarter and Nine Months Ended September 30, 2023 Unaudited Financial Results

Retrieved on: 
Monday, November 13, 2023
Research, Digital banking, Risk management, Administration, Research and development, OneConnect Financial Technology, ADS, Ecosystem, Marketing, Digital, Development, Operating cost, General Motors Gamma platform, Video game, Pharmaceutical industry

SHENZHEN, China, Nov. 13, 2023 /PRNewswire/ -- OneConnect Financial Technology Co., Ltd. ("OneConnect" or the "Company") (NYSE: OCFT and HKEX: 6638), a leading technology-as-a-service provider for financial services industry in China, today announced its unaudited financial results for the third quarter and nine months ended September 30, 2023.

Key Points: 
  • Gross profit in the third quarter of 2023 decreased to RMB295 million from RMB375 million for the same period in the prior year.
  • Gross margin decreased slightly by 0.1 percentage point from 35.1% in the third quarter of 2022 to 35.0% in the third quarter of 2023.
  • For a reconciliation of the Company's IFRS and non-IFRS gross margin, please refer to "Reconciliation of IFRS and Non-IFRS Results (Unaudited)".
  • For the third quarter of 2023, net cash used in operating activities was RMB190 million.

Theseus Pharmaceuticals Announces Process to Explore Strategic Alternatives

Retrieved on: 
Monday, November 13, 2023
Sale, Workforce, Cancer, Patient, Research and development, Development, Research

CAMBRIDGE, Mass., Nov. 13, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced that it is conducting a process exploring strategic alternatives to maximize shareholder value.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 13, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced that it is conducting a process exploring strategic alternatives to maximize shareholder value.
  • In conjunction with the strategic process, Theseus implemented a workforce reduction of approximately 72%.
  • This includes Theseus' President of Research and Development, William C. Shakespeare, Ph.D., who will continue to support the Company in a consulting capacity until June 30, 2024.
  • As of September 30, 2023, Theseus had cash, cash equivalents, and marketable securities of $225.4 million.

Intensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 13, 2023
Cisplatin, Component, Food, Therapy, Toxicity, Treatment, Sarcoma, ODD, US Foods, IND, Exercise, Intensity, Administration, Soft-tissue sarcoma, Research, IPO, Plague, Cancer, Survival, R, Research and development, Security, Neoplasm, Metastasis, Pharmaceutical industry, Security (finance), Cryptocurrency, Patient

SHELTON, Conn., Nov. 13, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage biotechnology company that applies novel engineered chemistry to discover and develop proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.

Key Points: 
  • "Metastatic soft tissue sarcoma continues to plague cancer patients who have poor survival outcomes and insufficient therapeutic options.
  • Presented Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society (CTOS).
  • In November, the Company presented positive data from its ongoing Phase 1/2 clinical trial of INT230-6 at the CTOS annual meeting.
  • In July, Intensity announced that it had closed its IPO with the full exercise of its over-allotment option.

AI and ML Integration Accelerate Cloud Collaboration Market Growth Amid Automation Trends

Retrieved on: 
Friday, November 10, 2023
Cloud, SME, Telecommunications, Investment, Insurance, Research, BFSI, Information technology, Artificial intelligence, WFH, Machine learning, COVID-19, Communication, Compound annual growth rate, R, Research and development, Health, AI, Education, Video game, Medical device, Network equipment provider, Growth

DUBLIN, Nov. 9, 2023 /PRNewswire/ -- The "Cloud Collaboration Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Nov. 9, 2023 /PRNewswire/ -- The "Cloud Collaboration Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global cloud collaboration market has achieved remarkable growth, reaching a size of US$ 42.9 Billion in 2022.
  • Several key trends are shaping the cloud collaboration market:
    Rise in Information Technology (IT) Industry: The global IT industry's substantial growth, coupled with increasing automation trends, is contributing to market expansion.
  • Integration of AI and ML: The integration of machine learning (ML) and artificial intelligence (AI) is enhancing communication and collaboration between teams, further fueling market growth.